SEC Comment Letter 0000000000-25-001958 to Medicus Pharma Ltd. (MDCX)
Medicus Pharma Ltd.
Date: Feb. 19, 2025 · CIK: 0001997296 · Accession: 0000000000-25-001958
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 024-12573
Letter
February 19, 2025 Raza Bokhari Executive Chairman and Chief Executive Officer Medicus Pharma Ltd. 300 Conshohocken State Rd., Suite 200 W. Conshohocken, PA 19428 Re:Medicus Pharma Ltd. Offering Statement on Form 1-A Filed February 14, 2025 File No. 024-12573 Dear Raza Bokhari: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Christopher Cummings, Esq.
Show Raw Text
February 19, 2025
Raza Bokhari
Executive Chairman and Chief Executive Officer
Medicus Pharma Ltd.
300 Conshohocken State Rd., Suite 200
W. Conshohocken, PA 19428
Re:Medicus Pharma Ltd.
Offering Statement on Form 1-A
Filed February 14, 2025
File No. 024-12573
Dear Raza Bokhari:
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence
of action by the staff. We also remind you that, following qualification of your Form 1-A,
Rule 257 of Regulation A requires you to file periodic and current reports, including a Form
1-K which will be due within 120 calendar days after the end of the fiscal year covered by the
report.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Christopher Cummings, Esq.